The FDA this month approved...

...Coherus BioSciences' Udenyca, a biosimilar to Amgen Inc.'s Neulasta, a blockbuster cancer therapy that boosts the white blood cell counts of chemotherapy patients. Neulasta already faces biosimilar competition from Mylan's Fulphila, though Neulasta holds preferred tier status for 13% of covered lives (plus an additional 21% with prior authorization or step therapy), compared to Fulphila's 1%. Udenyca will match Fulphila's 33% list price discount to Neulasta when it launches in January. 

SOURCE: MMIT Analytics, as of 11/20/18